AnaptysBio earnings beat by $5.58, revenue topped estimates

AnaptysBio (ANAB) reported Q1 EPS of $5.11, beating estimates by $5.58, with revenue of $27.49M, exceeding expectations. The stock closed at $45.95, down 34.18% over 3 months but up 46.48% year-over-year. Analysts revised EPS estimates, and InvestingPro rated its financial health as good.

Original reporting
Published Oct 10, 2026, 8:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 8:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ANAB
Bullish
high confidence
Mentioned
$ANAB
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ANABBullishHigh
01

Why it matters

The earnings surprise could trigger short-term buying pressure, but the company's small market cap may lead to heightened volatility.

02

Market read

Earnings beat provides a fresh catalyst for ANAB, likely prompting short-term price movement.

03

What to watch

Potential volatility from upcoming regulatory or clinical trial outcomes.

Relevance 7/10Novelty 8/10Timing: after-hours reaction

Background

AnaptysBio (NASDAQ: ANAB) is a clinical-stage biotech company. The earnings release was the first report of its Q1 results.

Company-level read

Ticker impact

$ANABBullishHigh confidence
Context

AnaptysBio reported Q1 EPS of $5.11, beating the estimate of -$0.47 and revenue of $27.49M vs $14.06M consensus.

Expected impact

likely upward pressure as investors price in the surprise earnings beat

Evidence & confidence

The surprise magnitude of both EPS and revenue exceeds expectations, prompting buying interest.

Market effects

Positive earnings may lift sentiment in the biotech sector.

Limited to US biotech investors.

Minor global impact, primarily US-focused.

Counterpoint

Some investors may view the beat as unsustainable given the company's small size.

Key entities

  • AnaptysBio

    Biotech firm reporting earnings beat.

Related articles

$ANABHighAI 8/10

ANAPTYSBIO, INC (ANAB): Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update • Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth • Jemperli approved in the U.S. as

$ANABHighAI 9/10

AnaptysBio, Inc. (ANAB) Gets FDA OK for Jemperli in MSI-H/dMMR Rectal Cancer

AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli as the first immunotherapy for adults with stage II-III MSI-H/dMMR locally advanced rectal cancer. The approval, based on AZUR-1 data, shows 68% of participants had no detectable cancer after one year, with no recurrences reported after 2+ years of follow-up. GSK will present full data at ESMO Congress 2026.

$ANABHighAI 9/10

AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo

AnaptysBio (ANAB) shares rose after partner GSK received FDA approval for an expanded label of anti-PD-1 therapy Jemperli. The approval allows marketing for a new cancer indication, accelerating regulatory action. ANAB's P/E ratio is 7.64x, below its 5-year median. Insider activity shows net selling. ANAB's GF Score is 43/100, reflecting mixed fundamentals.

$ANABHighAI 8/10

AnaptysBio gains as GSK granted FDA label expansion for Jemperli

AnaptysBio (ANAB) rose after partner GSK (GSK) received FDA approval to expand Jemperli's label for treating certain rectal cancers. The drug is now approved for adults with stage II/III MSI-H/dMMR locally advanced rectal cancer, a subset of 5%-10% of rectal cancers. The approval came earlier than the expected February 2027 date.